Filing Details
- Accession Number:
- 0001209191-23-051217
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-10-02 19:02:56
- Reporting Period:
- 2023-09-28
- Accepted Time:
- 2023-10-02 19:02:56
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1801777 | Applied Molecular Transport Inc. | AMTI | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1734779 | Shawn Cross | C/O Applied Molecular Transport Inc. 450 East Jamie Court South San Francisco CA 94080 | Ceo & Chair Of The Board | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-09-28 | 886,111 | $0.00 | 946,267 | No | 4 | A | Direct | |
Common Stock | Disposition | 2023-09-29 | 193,960 | $0.16 | 752,307 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Footnotes
- The reported shares are represented by restricted stock units, or RSUs. 443,055 RSUs vested upon signing of the Agreement and Plan of Merger dated as of September 21, 2023, among Cyclo Therapeutics, Inc., a Nevada corporation, Cameo Merger Sub, Inc., a Delaware corporation and the Issuer (the "Merger Agreement"). The remaining 443,056 RSUs vest as to 50% on the date that is five trading days following the filing of the proxy/prospectus relating to stockholder approval of the merger contemplated by the Merger Agreement (the "Form S-4") and 50% on the date the Form S-4 is declared effective by the SEC.
- Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of RSUs. This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.
- A portion of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.